The U.S. government has awarded Moderna $590 million to advance the development of its bird flu vaccine, as the country doubles down on efforts to tackle increasing infections in humans.
Bird flu has been detected in a Georgia commercial poultry flock for the first time since a countrywide outbreak in 2022.
Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.
HHS Allocates $590 Million to Speed Up the Development of mRNA Vaccines for Pandemic Influenza, Including an H5N1 (Bird Flu) Vaccine ...
The public health risk remains low, but bird flu variants have proven to be unpredictable, which is why the virus is a top ...
Georgia officials halted all in-state poultry sales, and the U.S. Department of Health and Human Services awarded $590 ...
Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...
US health officials announced Friday they were awarding $590 million to Moderna to develop mRNA vaccines against influenza, ...
Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...
Moderna secured a $590 million package from the U.S. Health and Human Services Department to accelerate the development of its bird influenza vaccine as concerns about a bird flu pandemic in humans ...
The US Department of Health and Human Services will award $590 million to Moderna to continue developing a vaccine to protect ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback